Lince-Deroche Naomi, Phiri Jane, Michelow Pam, Smith Jennifer S, Firnhaber Cindy
Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.
Cytology Unit, National Health Laboratory Service and Department of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.
PLoS One. 2015 Nov 16;10(11):e0141969. doi: 10.1371/journal.pone.0141969. eCollection 2015.
South Africa has high rates of HIV and HPV and high incidence and mortality from cervical cancer. However, cervical cancer is largely preventable when early screening and treatment are available. We estimate the costs and cost-effectiveness of conventional cytology (Pap), visual inspection with acetic acid (VIA) and HPV DNA testing for detecting cases of CIN2+ among HIV-infected women currently taking antiretroviral treatment at a public HIV clinic in Johannesburg, South Africa.
Method effectiveness was derived from a validation study completed at the clinic. Costs were estimated from the provider perspective using micro-costing between June 2013-April 2014. Capital costs were annualized using a discount rate of 3%. Two different service volume scenarios were considered. Threshold analysis was used to explore the potential for reducing the cost of HPV DNA testing.
VIA was least costly in both scenarios. In the higher volume scenario, the average cost per procedure was US$ 3.67 for VIA, US$ 8.17 for Pap and US$ 54.34 for HPV DNA. Colposcopic biopsies cost on average US$ 67.71 per procedure. VIA was least sensitive but most cost-effective at US$ 17.05 per true CIN2+ case detected. The cost per case detected for Pap testing was US$ 130.63 using a conventional definition for positive results and US$ 187.52 using a more conservative definition. HPV DNA testing was US$ 320.09 per case detected. Colposcopic biopsy costs largely drove the total and per case costs. A 71% reduction in HPV DNA screening costs would make it competitive with the conservative Pap definition.
Women need access to services which meet their needs and address the burden of cervical dysplasia and cancer in this region. Although most cost-effective, VIA may require more frequent screening due to low sensitivity, an important consideration for an HIV-positive population with increased risk for disease progression.
南非的艾滋病毒和人乳头瘤病毒感染率很高,宫颈癌的发病率和死亡率也很高。然而,如果能进行早期筛查和治疗,宫颈癌在很大程度上是可以预防的。我们估计了传统细胞学检查(巴氏涂片)、醋酸肉眼检查(VIA)和人乳头瘤病毒DNA检测在南非约翰内斯堡一家公共艾滋病毒诊所对目前正在接受抗逆转录病毒治疗的艾滋病毒感染女性中检测CIN2+病例的成本和成本效益。
方法有效性来自于在该诊所完成的一项验证研究。从提供者的角度,使用2013年6月至2014年4月期间的微观成本核算来估计成本。使用3%的贴现率对资本成本进行年度化。考虑了两种不同的服务量情景。采用阈值分析来探讨降低人乳头瘤病毒DNA检测成本的可能性。
在两种情景中,VIA成本最低。在服务量较高的情景中,VIA每例检查的平均成本为3.67美元,巴氏涂片为8.17美元,人乳头瘤病毒DNA检测为54.34美元。阴道镜活检每例检查平均成本为67.71美元。VIA的敏感性最低,但每检测到一例真正的CIN2+病例的成本效益最高,为17.05美元。使用传统的阳性结果定义,巴氏涂片检测每例检测成本为130.63美元,使用更保守的定义则为187.52美元。人乳头瘤病毒DNA检测每例检测成本为320.09美元。阴道镜活检成本在很大程度上推动了总成本和每例成本。人乳头瘤病毒DNA筛查成本降低71%将使其与保守的巴氏涂片定义具有竞争力。
女性需要获得满足其需求并解决该地区宫颈发育异常和癌症负担的服务。尽管VIA成本效益最高,但由于敏感性较低,可能需要更频繁的筛查,这对于疾病进展风险增加的艾滋病毒阳性人群是一个重要考虑因素。